IFNB1 and neoplasm: Here, a red/far‐red light‐controlled iPSC‐based vaccine (RIVA) based on the chimeric photosensory protein FnBphP and its interaction partner LDB3 is developed; RIVA preserves the intrinsic tumor antigens of iPSCs and enables optogenetic control of an immune adjuvant's (IFN‐β) expression under red light illumination.